Callan JMB Secures 60% Revenue Share in New Biologics Partnership, Targeting $12M-$25M Annual Revenue
CJMB has more than doubled off its 52-week low of $0.65 on light trading volume (0.1× avg).
Summary
Callan JMB signed a long-term support services agreement with Cavalry 1838 Equine Biosciences, giving it 60% of enterprise revenue from equine-derived biologics. The deal expands the Atlas Complex strategy and adds a recurring revenue stream with a base-case target of $12M-$25M annually within seven years. This follows a series of operational wins (Oregon VFC authorization, Alabama State University partnership) but comes amid severe financial distress—a going concern warning, Nasdaq delisting notice, and a pending highly dilutive $10M Williston Basin acquisition. The partnership provides a potential lifeline if Cavalry 1838 commercializes successfully, but revenue is years away and the company's near-term survival hinges on the ATM program and reverse split to regain Nasdaq compliance.
At the time of this announcement, CJMB was trading at $1.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $0.65 to $5.61. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.